ArticleFrontiers in oncology2026
Predictors of sentinel lymph node mapping failure in endometrial cancer: a retrospective multicenter study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study evaluated risk factors for indocyanine green (ICG) sentinel lymph node (SLN) mapping failure in endometrial cancer patients and assessed their value in predicting SLN mapping failure at the individual patient level. Methods: We conducted a retrospective study of endometrial cancer patients who underwent ICG-guided SLN biopsy. Risk factors for SLN mapping failure were identified using univariate and multivariate logistic regression analyses. Additionally, an imbalanced random forest (RF) algorithm was trained to predict SLN mapping success or failure. Predictive modeling was used to complement traditional statistical inference by translating population-level associations into patient-specific risk estimates. Results: A total of 190 patients were included, of whom 35 experienced SLN mapping failure. Univariate analyses showed that age 65 years and over (OR = 2.87, 95% CI 1.31-6.26; p = 0.007) and serous histological subtype (OR = 4.12, 95% CI 1.41-12.0; p = 0.006) were significantly associated with mapping failure. Multivariate analysis revealed that only age remained statistically significant (OR = 1.07 per year; 95% CI 1.02-1.13; p = 0.006). No significant associations were observed for obesity, morbid obesity, tumor grade, or FIGO stage. The discriminative ability of the RF model was poor (cross-validated AUC = 0.58, 95% CI 0.47-0.69). Conclusion: We suggest-on average-age 65 years and over and a serous histological subtype are risk factors for SLN mapping failure. However, the presence of these risk factors in an individual patient does not reliably predict SLN mapping failure. Additionally, more specific predictors may be needed for accurate individualized prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.